Research programme: anti-MUC1 monoclonal antibodies - Vaxil BiotherapeuticsAlternative Names: Anti-MUC1 SP vaccine companion diagnostic - Vaxil Biotherapeutics; Anti-MUC1 therapeutic cancer vaccine companion diagnostic - Vaxil BioTherapeutics; ImMucin™ companion diagnostic - Vaxil BioTherapeutics; MUC1 companion diagnostic - Vaxil BioTherapeutics; SPmAb 2.1; SPmAb 6
Latest Information Update: 20 Jun 2016
At a glance
- Originator Vaxil BioTherapeutics
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer